Compile Data Set for Download or QSAR

Found 3 hits of ic50 for monomerid = 50101762   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101762 ((S)-2-Benzyloxycarbonylamino-3-{[5-(2-guanidinocar...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(s1)C1CC1C(=O)NC1=NCCCN1)NC(=O)OCc1ccccc1 |t:21| Show InChI InChI=1S/C24H27N5O6S/c30-20(29-23-25-9-4-10-26-23)16-11-15(16)18-7-8-19(36-18)21(31)27-12-17(22(32)33)28-24(34)35-13-14-5-2-1-3-6-14/h1-3,5-8,15-17H,4,9-13H2,(H,27,31)(H,28,34)(H,32,33)(H2,25,26,29,30)/t15?,16?,17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	41	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101762 ((S)-2-Benzyloxycarbonylamino-3-{[5-(2-guanidinocar...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(s1)C1CC1C(=O)NC1=NCCCN1)NC(=O)OCc1ccccc1 |t:21| Show InChI InChI=1S/C24H27N5O6S/c30-20(29-23-25-9-4-10-26-23)16-11-15(16)18-7-8-19(36-18)21(31)27-12-17(22(32)33)28-24(34)35-13-14-5-2-1-3-6-14/h1-3,5-8,15-17H,4,9-13H2,(H,27,31)(H,28,34)(H,32,33)(H2,25,26,29,30)/t15?,16?,17-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	60	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-IIb/beta-3 (Homo sapiens (Human))	BDBM50101762 ((S)-2-Benzyloxycarbonylamino-3-{[5-(2-guanidinocar...) Show SMILES OC(=O)[C@H](CNC(=O)c1ccc(s1)C1CC1C(=O)NC1=NCCCN1)NC(=O)OCc1ccccc1 |t:21| Show InChI InChI=1S/C24H27N5O6S/c30-20(29-23-25-9-4-10-26-23)16-11-15(16)18-7-8-19(36-18)21(31)27-12-17(22(32)33)28-24(34)35-13-14-5-2-1-3-6-14/h1-3,5-8,15-17H,4,9-13H2,(H,27,31)(H,28,34)(H,32,33)(H2,25,26,29,30)/t15?,16?,17-/m0/s1	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	2.45E+3	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair